Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Status:	Completed
Conditions:	Neurology
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	Any
Updated:	11/18/2012
Start Date:	December 2011
End Date:	March 2013

A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER

A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to
evaluate the safety and tolerability and the effect of dalfampridine extended release (ER)
tablets on sensorimotor function

Inclusion Criteria:

- A diagnosis of CP

- No previous use of any dalfampridine formulation

- Ability to perform all the required study procedures. Subjects should be capable of
fully extending and flexing both hands

Exclusion Criteria:

- Presence of any progressive neurological disease

- Severe CP defined as the requirement to use a wheelchair at all times and a care
taker for constant assistance in daily activities. This definition includes spastic
quadriplegia

- Pregnant or breastfeeding

We found this trial at

sites

Gillette Children's Specialty Healthcare

St. Paul, Minnesota 55101

from

St. Paul, MN